Incyte Biosciences International Sàrl
16
1
3
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
37.5%
6 terminated/withdrawn out of 16 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
133%
8 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)
Role: collaborator
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Role: lead
Vitiligo Registry for Adults and Children in the UK
Role: collaborator
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Role: lead
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Role: lead
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Role: lead
Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)
Role: collaborator
Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery
Role: collaborator
Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
Role: collaborator
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Role: lead
Study in Patients With Chronic Leukemia
Role: collaborator
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Role: lead
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Role: lead
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
Role: lead
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Role: lead
A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"
Role: lead
All 16 trials loaded